[8-K] Medicus Pharma Ltd. Reports Material Event

Rhea-AI Filing Summary

On 29 July 2025, U-BX Technology Ltd. (symbol: UBXG) filed a Form 6-K announcing that its Board of Directors approved and adopted a new 2025 Equity Incentive Plan, effective the same day. No financial results or share-based figures were disclosed in the filing; the complete plan is provided as Exhibit 99.1.

The sole purpose of this report is to notify investors of the plan’s adoption, which is expected to grant equity awards to employees, directors and other service providers. Potential effects include improved talent retention and possible future share dilution, but specific terms—such as award limits, eligibility criteria or dilution caps—were not included in the 6-K text.

Positive

• Adoption of a formal 2025 Equity Incentive Plan may improve alignment between management, employees and shareholders, supporting retention and performance motivation.

Negative

• Potential share dilution from future equity awards; exact magnitude unknown due to lack of disclosed share reserve or issuance limits.

Insights

Equity Compensation Analyst

TL;DR: New equity plan aligns incentives but could dilute shareholders; impact neutral until terms known.

The 6-K merely states that a 2025 Equity Incentive Plan is in place, with details relegated to Exhibit 99.1. Equity programs generally foster retention and performance alignment, a positive governance signal for growth companies. However, absent information on the plan’s share reserve, award types, or dilution limits, investors cannot quantify dilution risk or expense impact (e.g., future ASC 718 charge). Until specifics are reviewed, the filing is operationally routine and has limited immediate valuation impact.

false 2025-07-29 0001997296 Medicus Pharma Ltd. 0001997296 2025-07-29 2025-07-29 0001997296 exch:XNCM mdcx:CommonSharesNoParValueMember 2025-07-29 2025-07-29 0001997296 exch:XNCM mdcx:WarrantsEachExercisableForOneCommonShareAtAnExercisePriceOfFourPointSixFourPerShareMember 2025-07-29 2025-07-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2025

MEDICUS PHARMA LTD.
(Exact name of registrant as specified in its charter)

Ontario	001-42408	98-1778211
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

300 Conshohocken State Road, Suite 200
Conshohocken, Pennsylvania, United States 19428
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: (610) 540-7515

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common shares, no par value		MDCX		NASDAQ Capital Market
Warrants, each exercisable for one common share at an exercise price of $4.64 per share		MDCXW		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On July 29, 2025, Medicus Pharma Ltd. (the "Company") and Deloitte LLP ("Deloitte") entered into an engagement letter (the "Engagement") whereby Deloitte was appointed as the exclusive lead financial adviser to the Company for the purpose of finding one or more partners for an out-licensing transaction for Doxorubicin Microneedle Array ("D-MNA") for the treatment of Basal Cell Carcinoma ("BCC") in adults, whether by license, option, or other agreed structure or mechanism (collectively, a "Transaction"). Under the terms of the Engagement the Company will pay Deloitte a retainer as well as a contingent success fee in the event that a Transaction is consummated.

Forward Looking Statements

Certain information in this Current Report on Form 8-K constitutes "forward-looking statements" under applicable securities laws. "Forward-looking statements" are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company's intention to out-license D-MNA for BCC, whether by a Transaction or otherwise, and the ability of the Company to enter into or to consummate a Transaction. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2024 (the "Annual Report"), and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this Current Report on Form 8-K are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Readers are cautioned that the foregoing list is not exhaustive, and readers are encouraged to review the Annual Report accessible on the Company's profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

MEDICUS PHARMA LTD.
By:	/s/ Raza Bokhari
Name:	Dr. Raza Bokhari
Title:	Executive Chairman and Chief Executive Officer

Dated: July 30, 2025

FAQ

What did U-BX Technology Ltd. announce in its July 2025 Form 6-K?

The Board approved and adopted the 2025 Equity Incentive Plan effective 29 July 2025.

Does the filing disclose how many shares are reserved under the 2025 plan?

No, the 6-K text does not provide share reserve figures; those details are in Exhibit 99.1.

Why is an equity incentive plan significant to UBXG investors?

It can align employee incentives with shareholder value but may also lead to future dilution.

Are there any financial results or earnings figures in this 6-K?

No financial performance data is included; the report is strictly about the equity plan.

When did the 2025 Equity Incentive Plan become effective?

The plan became effective on 29 July 2025.